Mineralys Therapeutics reported a net loss of $43.3 million for the second quarter ended June 30, 2025, compared to $41.0 million for the same period in 2024. Research and Development (R&D) expenses decreased slightly to $38.3 million from $39.3 million year-over-year, primarily due to the conclusion of the lorundrostat pivotal program.
The company's cash, cash equivalents, and investments totaled $324.9 million as of June 30, 2025, compared to $198.2 million at December 31, 2024. This cash position is expected to fund operations into 2027, providing a solid financial runway.
Mineralys highlighted the positive results from its Launch-HTN, Advance-HTN, and Explore-CKD trials, which have positioned the company for its New Drug Application (NDA) strategy. A pre-NDA meeting with the FDA is scheduled for the fourth quarter of 2025, and the Explore-OSA Phase 2 trial is ongoing with topline results anticipated in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.